Treatment of Haemophilus influenzae Pneumonia in Adults with Community-Acquired Pneumonia and P. aeruginosa Risk Factors
Clinical Scenario
This protocol addresses adult inpatients with community-acquired pneumonia (CAP) who also carry locally validated risk factors for Pseudomonas aeruginosa: prior respiratory isolation of P. aeruginosa, or recent hospitalisation with parenteral antibiotic exposure in the preceding 90 days together with locally validated risk factors for P. aeruginosa.
Risk factor guidance: Empiric coverage for P. aeruginosa is recommended only when locally validated risk factors are present. The most consistently strong individual risk factors are prior respiratory isolation of P. aeruginosa and/or recent hospitalisation with parenteral antibiotic exposure.
Treatment Approach (Partial Overview)
The regimen extends the standard community-acquired pneumonia framework with added empiric coverage targeting P. aeruginosa. Cultures are obtained at initiation to enable deescalation or to confirm the need for continued directed therapy. The complete agent selection, sequencing, and deescalation algorithm are available in the full protocol.
Clinical Goals
The target is clinical stability — resolution of vital-sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), the ability to eat, and normal mentation. Clinical stability is expected within 48 to 72 hours, with antibiotic therapy continued for no less than a total of 5 days.
References
DOI: 10.1164/rccm.201908-1581ST
- We recommend clinicians only cover empirically for MRSA or P. aeruginosa in adults with CAP if locally validated risk factors for either pathogen are present (strong recommendation, moderate quality of evidence).
- The most consistently strong individual risk factors for respiratory infection with MRSA or P. aeruginosa are prior isolation of these organisms, especially from the respiratory tract, and/or recent hospitalization and exposure to parenteral antibiotics.
- Add coverage for P. aeruginosa and obtain cultures to allow deescalation or confirmation of need for continued therapy.
- We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).
- As most patients will achieve clinical stability within the first 48 to 72 hours, a total duration of therapy of 5 days will be appropriate for most patients.
View source ↗